About Wobble Genomics
Wobble Genomics is a company based in Edinburgh (United Kingdom) founded in 2020 by Richard Kuo. Wobble Genomics has raised $12.46 million across 2 funding rounds from investors including Mercia, BGFG and Eos Capital Advisors. The company has 6 employees as of June 30, 2022. Wobble Genomics operates in a competitive market with competitors including Metabolon, Maze Therapeutics, Alector, Seer and Tango Therapeutics, among others.
- Headquarter Edinburgh, United Kingdom
- Employees 6 as on 30 Jun, 2022
- Founders Richard Kuo
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Wobble Genomics Limited
- Date of Incorporation 06 Apr, 2021
- Jurisdiction EDINBURGH, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12.46 M (USD)
in 2 rounds
-
Latest Funding Round
$10.81 M (USD), Series A
Dec 22, 2023
-
Investors
Mercia
& 6 more
-
Employee Count
6
as on Jun 30, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Wobble Genomics
Unlock access to complete
Unlock access to complete
Funding Insights of Wobble Genomics
Wobble Genomics has successfully raised a total of $12.46M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $10.81 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Wobble Genomics
Wobble Genomics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Mercia, BGFG and Eos Capital Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Deep tech venture capital firm investing in European and global startups.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investment in science and technology is managed by Eos.
|
Locked | Locked | Locked |
Investor details for Wobble Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Wobble Genomics
Investment portfolio details for Wobble Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Wobble Genomics
Detailed financials for Wobble Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Wobble Genomics Comparisons
Peer comparison for Wobble Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Wobble Genomics
Wobble Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Maze Therapeutics, Alector, Seer and Tango Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| Locked | Locked | Locked |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| Locked | Locked | Locked |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
|
| Locked | Locked | Locked |
Proteomics platform developed for early cancer and neurological disease detection.
|
|
| Locked | Locked | Locked |
Novel cancer drugs are developed using synthetic lethality screening.
|
|
| Locked | Locked | Locked |
NeoPhore is focused on cancer neoantigen evolution therapies.
|
Detailed competitors of Wobble Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Wobble Genomics
Complete news archive for Wobble Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Wobble Genomics
Wobble Genomics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Wobble Genomics is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Wobble Genomics is a funded company, having raised a total of $12.46M across 2 funding rounds to date.
As of Jun 30, 2022, the latest employee count at Wobble Genomics is 6.
Wobble Genomics was founded in 2020 in Edinburgh, United Kingdom, within the genomics sector. A platform for nucleic acid biomarker discovery is offered, incorporating cDNA normalization technology called Level-Up to support non-targeted sequencing for biomarker identification. TAMA RNA sequencing bioinformatics software is also provided to facilitate gene detection. Operations focus on these tools for research applications in the United Kingdom.
Wobble Genomics's top competitors include Alector, Lexicon Pharmaceuticals and Maze Therapeutics.
Wobble Genomics has 7 investors. Key investors include Mercia, BGFG, Eos Capital Advisors, IQ Capital, and Old College Capital.